Europe Rare Sugar Market size exceeded USD 200 million in 2019 and is anticipated to register a growth rate of 3.5% between 2020 and 2026.
Rare sugars are monosaccharides that rarely occur in nature such as D-allose, D-tagatose, D-allulose, xylitol, L-ribose, etc. and can be obtained from biochemical processes such as enzymatic conversion and fermentation. Rare sugars can suppress hyperglycemia and lipid accumulation which helps in preventing diabetes and obesity. Rare sugars contain less calories that normal sugars, hence have gained popularity among consumers as substitutes for sugars and artificial sweeteners such as fructose, sucrose, and HFS.
Utilization of rare sugars has gained traction owing to rising consumer awareness on use of sugar alternatives and reducing calorie content in diets and creating lucrative growth opportunities for the Europe rare sugar industry.
The allulose segment is predicted to register a growth of over 6.5% from 2020 to 2026. Allulose is a low-calorie rare sugar or monosaccharide that has similar characteristics that of fructose and is naturally present in fruits like raisins, jackfruits, and figs in small quantities. Moreover, allulose is also used in food applications as a sugar alternative as it replicates functional properties of sugar and has less calories.
Consumer awareness regarding health, diet, and chronic diseases has soared in recent years owing to increase in the number of individuals suffering from diabetes and obesity. The number of people suffering from diabetes was over 60 million in 2019 and the number is estimated to reach USD 65 million by the end of 2025. Rise in the number of individual suffering from diabetes is expected to boost the demand for low calorie sweeteners and projected to trigger the Europe allulose sector.
Drugs manufactured from natural sugar compounds can cause biochemical reactions during cellular processes, however, medicines produced using rare sugars do not interfere with cellular processes. Therefore, rare sugars can be of high importance in commercia synthesis of anti-cancer drugs and antiviral drugs. Rising prevalence of breast cancer, colorectal cancer, prostate cancer, and lung cancer in European countries should accelerate the demand for anti-cancer drugs, which may stimulate the utilization of rare sugars in producing anti-cancer drugs.
The demand for dietary supplements has increased in UK during the forecast period, owing to growing consumer awareness and increasing number of individuals suffering from diabetes. Consumers are adopting healthy diets and nutritional foods that contain low calorie and low sugar foods for treating and preventing chronic diseases.
Europe rare sugar market share is significantly competitive with major players including Douglas Laboratories Europe, DuPont de Nemours, Inc., Tate & Lyle, Zhangjiagang Specom Biochemical Co., Ltd., Nutraceuticals Group, The Sanwa Starch Co., Ltd., Bonumose LLC, Samyang Corporation, Matsutani Chemical Industry Co., Ltd., Sweet Cures, and Ingredion Incorporated.
Key players are engaged in several activities in order to strengthen its market position. For instance, in 2021, American Sugar Refining invested in Bonumose, Inc. for producing and commercialising tagatose and allulose. Bonumose, Inc. will focus on production of tagatose and allulose and focus on developing R&D pipeline.